Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis

Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5 (IL-5) that reduces blood eosinophil counts, as an add-on therapy to glucocorticoid treatment, results in more accrued weeks in remission, reducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Condreay, Lynn D., Parham, Laura R., Qu, Xiaoyan A., Steinfeld, Jonathan, Wechsler, Michael E., Raby, Benjamin A., Yancey, Steven W., Ghosh, Soumitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Genes and Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316687/
https://www.ncbi.nlm.nih.gov/pubmed/32009195
http://dx.doi.org/10.1007/s00296-020-04523-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316687/
https://www.ncbi.nlm.nih.gov/pubmed/32009195
http://dx.doi.org/10.1007/s00296-020-04523-6

Ejemplares similares